Pharmaceuticals

Rising Incidence Of Thrombotic Disorders Fueling The Growth Of The Market Due To Increasing Cases Of Blood Clots And Related Health Complications Is Supporting Development Across The Factor XII Inhibitors Market

May 19, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Expansion Is Expected For The Factor XII Inhibitors Market Over The Forecast Period?

The factor xii inhibitors market has experienced substantial growth in recent years. It is anticipated to expand from $1.4 billion in 2025 to $1.55 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.1%. This historical growth can be attributed to advancements in coagulation biology research, a rising incidence of thrombotic disorders, the limitations of traditional anticoagulants, early positive clinical results for fxii inhibition, and increasing investment in rare and specialty therapeutics.

The factor xii inhibitors market size is anticipated to undergo substantial growth in the upcoming years. It is projected to expand to $2.34 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 10.8%. The expansion during the forecast period is fueled by the increase in late-stage clinical trials, a rising need for safer antithrombotic therapies, growing adoption of precision medicine, enhanced regulatory support for innovative anticoagulants, and the broadened application of fxii inhibitors in inflammatory indications. Key developments expected in this period include the increased creation of non-bleeding anticoagulant treatments, a heightened emphasis on targeted coagulation pathway modulation, a growing clinical assessment of fxii selective inhibitors, the expansion of RNA-based and peptide therapeutics, and the improved implementation of precision drug design.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30278&type=smp

Which Core Factors Are Supporting The Expansion Of The Factor XII Inhibitors Market?

An anticipated increase in thrombotic disorders is projected to boost the expansion of the factor XII inhibitors market moving ahead. These conditions, where blood clots develop in veins or arteries, can obstruct blood flow and lead to severe health issues. The growing occurrence of inactive lifestyles, which leads to inadequate blood circulation and an elevated risk of clot development, is contributing to the rise in thromboembolic disorders. In managing thrombotic disorders, Factor XII inhibitors prevent pathological clot formation by interrupting the contact activation pathway, thus preserving normal blood clotting. This approach offers effective control over thrombosis while reducing the likelihood of bleeding. For instance, as reported in January 2025 by the Centers for Disease Control and Prevention (CDC), a US government agency, approximately 900,000 individuals in the United States suffer from venous thromboembolism, with an estimated 60,000-100,000 Americans dying each year, and numerous others facing lasting complications. Consequently, the escalating frequency of thrombotic disorders is stimulating the expansion of the Factor XII inhibitors market.

How Is Segment Classification Applied In The Factor XII Inhibitors Market?

The factor xii inhibitors market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Small Molecule Inhibitors, Other Drug Types

2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

3) By Application: Hereditary Angioedema, Thrombosis, Inflammatory Disorders, Other Applications

4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Bispecific Monoclonal Antibodies, Single-Chain Variable Fragment (scFv) Antibodies

2) By Small Molecule Inhibitors: Direct Factor XII Inhibitors, Allosteric Factor XII Inhibitors, Reversible Inhibitors, Irreversible Inhibitors, Peptidomimetic Inhibitors

3) By Other Drug Types: Peptide-Based Inhibitors, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotides, Combination Therapies

What Trends Are Influencing The Factor XII Inhibitors Market Outlook?

Major companies operating in the Factor XII Inhibitors market are prioritizing the development of innovative products, such as anti-FXIIa monoclonal antibodies, to enhance therapeutic precision and improve treatment effectiveness. Anti-FXIIa monoclonal antibodies are specifically designed biologics that work by inhibiting activated factor XII, preventing abnormal clot formation while simultaneously preserving normal hemostasis. As an illustration, in February 2025, CSL Behring GmbH, a Germany-based biopharmaceutical company, secured manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for ANDEMBRY (garadacimab) subcutaneous (S.C.) injection 200 mg pens. This novel, human anti-activated factor XII monoclonal antibody has been approved for the prevention of acute attacks of hereditary angioedema (HAE). Its mechanism involves targeting activated factor XIIa, a key instigator in the onset of HAE attacks, and it is conveniently administered via a subcutaneous injection pen.

Who Are The Companies Shaping The Factor XII Inhibitors Market Landscape?

Major companies operating in the factor xii inhibitors market are Taylor & Francis Group, Santa Cruz Biotechnology Inc., CSL Limited, Bridge Medicines Inc., KalVista Pharmaceuticals Inc., Ovid Technologies Inc., Affinity Biologicals Inc., Lunac Therapeutics Ltd., Grantome LLC

Access The Complete Factor XII Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/report/global-factor-xii-inhibitors-market-report

Which Region Leads The Factor XII Inhibitors Market By Size?

North America was the largest region in the factor XII inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the factor xii inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Factor XII Inhibitors Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=30278&type=smp

Browse Through More Reports Similar to the Global Factor XII Inhibitors Market 2026, By The Business Research Company

Tumor Necrosis Factor Inhibitor Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report

Kinase Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

Enzyme Inhibitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795